Access Pharma (OTC:ACCP) will Present at Growth Stock Conference on July 30 |
 |
 |
| Wednesday, 22 July 2009 08:41 |
|
"We are pleased to have the opportunity to present Access Pharmaceuticals to the large group of institutional and retail investors that attend Jessup's annual growth stock conference," stated Jeffrey B. Davis, Access' President & CEO. "The conference provides a forum for Access to highlight in many product programs, and specifically the very significant and positive initial results and feedback from the commercial launch of MuGard, our FDA approved treatment for oral mucositis. Initial clinical feedback and experience exceeds our expectations." A video presentation for MuGard is available at YouTube, in addition to more information and links at the Company's newsroom website. Please visit the research section of BioMedReports.com to view or download PDF stock research reports for Access written by Griffin Securities from April 2009 with a 12-month price target of $7.50 (which equates to a fully diluted market cap of about $164 million) and Dawson James from July 2009 with a $4 price target (3X estimated 2011 revenue), in addition to the Company's most recent corporate presentation. Access also has a proactive management team which holds a large financial stake in the Company and has established a social media presence on Facebook, Twitter, and LinkedIn. Click here for the most recent overview article on Access Pharma at BioMedReports.
BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section Add this page to your favorite Social Bookmarking websites            |
DALLAS -- 
Free Phone Trade Alerts
